Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAMORPH PF vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of moderate to severe pain when continuous opioid analgesia is needed for an extended period,Off-label: epidural or intrathecal administration for postoperative pain,Off-label: treatment of dyspnea in palliative care
Relief of moderate to moderately severe pain
0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life of morphine is approximately 2-4 hours in adults. In neonates and elderly, half-life may be prolonged (up to 4.5-6.5 hours). Context: half-life may be extended in renal impairment due to accumulation of active metabolites.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via glucuronidation by UGT2B7 to morphine-3-glucuronide (M3G, inactive) and morphine-6-glucuronide (M6G, active); minor metabolism via CYP2D6 to normorphine.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, with 10% as unchanged morphine). Biliary/fecal excretion accounts for less than 10%.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
30-35% bound to albumin.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
3-5 L/kg (range 1-6 L/kg). Clinical meaning: indicates extensive tissue distribution.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Epidural/Intrathecal: effectively 100% at site of action (systemic bioavailability from epidural absorption is ~30-40% due to first-pass metabolism). Oral: 20-40% (not relevant for DURAMORPH PF).
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
GFR 50-90 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and extend dosing interval; GFR <10 m L/min: avoid use or reduce dose by 50% and administer every 6-8 hours with close monitoring.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50% and monitor; Child-Pugh Class C: avoid use or reduce dose by 50% and extend dosing interval.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Epidural: 0.03 to 0.05 mg/kg as a single dose, may repeat every 4-6 hours; continuous infusion: 0.002 to 0.008 mg/kg/hour. Intrathecal: 0.01 to 0.02 mg/kg as a single dose. Intravenous: 0.05 to 0.1 mg/kg every 2-4 hours prn.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Reduce initial dose by 25-50% and titrate cautiously due to increased sensitivity and risk of respiratory depression. Use non-PVC tubing and avoid in renal impairment.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROID; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Ensure proper patient selection, monitoring, and dispensing.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients; central nervous system depression; serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; severe hypotension; use in patients with head injury; use in patients with biliary tract disease; use in patients with pancreatic disease; use in patients with renal impairment; use in patients with hepatic impairment; use in patients with respiratory conditions; use in patients with gastrointestinal obstruction; use in patients with prostatic hyperplasia; use in patients with urinary retention; use in patients with hypothyroidism; use in patients with adrenocortical insufficiency; use in patients with toxic psychosis; use in patients with alcoholism; use in patients with delirium tremens; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with sleep apnea; use in patients with myxedema; use in patients with chronic obstructive pulmonary disease; use in patients with cor pulmonale; use in patients with respiratory depression; use in patients with acute or severe bronchial asthma; use in patients with paralytic ileus; use in patients with hypersensitivity to morphine; use in patients with gastrointestinal obstruction; weaning from opioids; physical dependence; withdrawal; tolerance; impaired mental or physical abilities; driving; operating machinery; risk of overdose; accidental ingestion; neonatal opioid withdrawal syndrome; concomitant use with alcohol; concomitant use with benzodiazepines; concomitant use with CNS depressants; abuse potential; monitoring; pregnancy; lactation; renal impairment; hepatic impairment; elderly; pediatric; recent intracranial surgery; increased intracranial pressure; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; severe pulmonary disease; respiratory depression; sleep-related breathing disorders; drug dependence; misuse; addiction; abuse; diversion; storage and disposal.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hypersensitivity to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction, including paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy; respiratory depression in the absence of resuscitative equipment; upper airway obstruction; status asthmaticus; severe chronic obstructive pulmonary disease; cor pulmonale; severe obesity; sleep apnea syndrome; myxedema; delirium tremens; acute alcoholism; increased intracranial pressure; head injury; intracranial lesions; impaired consciousness; coma; convulsive disorders; hypotension; hypovolemia; biliary tract surgery; suspected surgical abdomen; pancreatitis; prostatic hyperplasia; urethral stricture; urinary retention; use in pregnancy when premature delivery is anticipated; during labor when delivery of a premature infant is anticipated; during labor when narcotic antagonist is not available; use in breastfeeding; use in children less than 18 years (except as directed by a physician).
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid alcohol and grapefruit juice for at least 24 hours after administration. Alcohol potentiates CNS depression and respiratory effects. No specific food restrictions beyond standard postoperative diet; however, patients should avoid large meals if nauseated. Maintain adequate fluid and fiber intake to mitigate constipation.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS) after delivery. Not associated with major congenital malformations in human studies, but risk-benefit must be assessed.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Morphine is excreted into breast milk. M/P ratio is approximately 2.5. Relative infant dose is about 9-10% of maternal weight-adjusted dose. Use with caution; monitor for infant drowsiness, respiratory depression, and constipation. American Academy of Pediatrics considers morphine compatible with breastfeeding, but avoid during labor and delivery due to potential neonatal respiratory depression.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No established dose adjustment guidelines for pregnancy. Pharmacokinetic changes: Increased volume of distribution and clearance in pregnancy may lower peak concentrations, but clinical significance is unclear. Use the lowest effective dose for the shortest duration. For epidural/intrathecal use, doses are typically adjusted by clinician based on maternal response and fetal status. Avoid high doses in third trimester due to risk of neonatal respiratory depression.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
DURAMORPH PF is a preservative-free morphine sulfate solution indicated for epidural or intrathecal administration. Onset of analgesia occurs within 10-15 minutes after epidural injection and peaks at 30-60 minutes; intrathecal onset is faster (5-10 minutes) with duration up to 24 hours. Due to risk of delayed respiratory depression, patients must be monitored in a setting equipped for resuscitation for at least 24 hours after administration. Naloxone should be readily available. Do not use if solution is discolored or contains precipitate. Avoid concurrent use with MAOIs or within 14 days of discontinuation.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
This medication is given directly into the spine to control severe pain. You will be closely monitored in the hospital. Report any trouble breathing, severe drowsiness, or itching.,Do not drive or operate machinery for at least 24 hours after administration. Avoid alcohol and sedatives, which may increase respiratory depression.,You may experience nausea, vomiting, constipation, or urinary retention. Notify your healthcare provider if these become severe.,If you have a history of opioid addiction, head injury, asthma, or kidney/liver disease, inform your doctor before treatment.,Do not breastfeed for 24 hours after receiving this medication. Inform all healthcare providers that you have received an intrathecal opioid.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAMORPH PF vs ANEXSIA, answered by our medical review team.
DURAMORPH PF is a Opioid Analgesic that works by Morphine is a full opioid agonist that primarily acts on mu-opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. It also interacts with kappa and delta receptors. It inhibits ascending pain pathways and alters pain perception and response.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAMORPH PF and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAMORPH PF is: 0.8 to 10 mg via epidural injection as a single dose or via continuous epidural infusion at 0.1 to 1 mg/hour. For intrathecal use: 0.2 to 1 mg as a single dose. Intravenous: 2 to 10 mg for analgesia every 2-4 hours as needed.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAMORPH PF and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAMORPH PF is classified as Category C. Preservative-free morphine (Duramorph PF) is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of neural tube defects and skeletal a. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.